On Thursday, Shares of Northstar Realty Finance Corp (NYSE:NRF), lost -0.44% to $15.82.
Northstar Realty Finance Corp, declared that NorthStar Realty Europe Corp. (“NorthStar Realty Europe” or “NRE”), a current wholly-owned partner of NorthStar Realty Finance, has commenced a private offering of $300 million aggregate principal amount of NorthStar Realty Europe’s senior stock-settlable notes due December 2016, plus up to an additional $60 million principal amount of notes that may be issued at the option of the initial purchaser within 30 days of the initial sale of the notes. The notes will be senior unsubordinated and unsecured obligations of NorthStar Realty Europe, and each of NorthStar Realty Finance and its operating partnership, NorthStar Realty Finance Limited Partnership, will guarantee payments on the notes. Subject to specified conditions being met, counting completion of the planned spin-off of NRE by NorthStar Realty Finance, the listing of NRE common stock, $0.01 par value, and public notice at least 60 days preceding to maturity, NRE may elect to settle all or part of the principal value of the notes in NRE common stock in lieu of cash, in which case the number of shares delivered per note will be based on NRE common stock prices during a measurement period right away preceding the maturity date.
NorthStar Realty Europe intends to use the net proceeds of the offering for general corporate purposes, which may comprise, among other things:
- the funding of acquisitions, counting additional European commercial real estate and other assets; and
- the repayment of NorthStar Realty Finance’s indebtedness, counting amounts outstanding under its corporate revolving credit facility, which accrues interest at a per annum rate equal to LIBOR plus 3.50% (or 3.68% per annum as of June 4, 2015) and is due on August 5, 2017.
NorthStar Realty Finance Corp. is a real estate investment trust launched and managed by NorthStar Asset Administration Group. The fund invests in the real estate markets of the United States.
Shares of Coca-Cola Enterprises Inc (NYSE:CCE), declined -0.71% to $ 43.16, during its last trading session.
Coca-Cola Enterprises Inc, launched its tenth annual Corporate Responsibility and Sustainability report, which comprises its most ambitious commitments to date. The new targets provide a strong response to stakeholder feedback and address issues around well-being, the environment and employability which affect the communities in which CCE operates.
The commitments comprise:
- Reducing calories per liter across CCE’s entire portfolio by 10 percent by 2020;
- Halving the carbon footprint of its business by 2020;
- Ensuring that 40 percent of the PET it uses is recycled PET and/or PET from renewable materials by 2020;
- Supporting the skills development and learning needs of 250,000 young people every year.
Coca-Cola Enterprises, Inc. produces, distributes, and markets non-alcoholic beverages in Belgium, continental France, Great Britain, Luxembourg, Monaco, the Netherlands, Norway, and Sweden.
Finally, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), ended its last trade with -1.80% loss, and closed at $56.13.
Isis Pharmaceuticals, declared that it has been added to the Russell 1000 Index, effective June 26, 2015. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and comprises about 1000 of the largest securities based on a combination of their market cap and current index membership.
“We are happy to be added to this important index, which assists to raise awareness of our company even more broadly among investors,” said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals. “Our promotion to the Russell 1000 index is a reflection of the substantial growth in Isis’ valuation, the positive results achieved with our pipeline of antisense drugs and the success of our business strategy.”
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
